Pruritus Control With PPAR Agonists in PBC

Author(s):

Nancy Reau, MD,John Vierling, MD, FACP, FAASLD, AGAF

Key Takeaways

Pruritus affects over 80% of PBC patients, impacting quality of life and treatment adherence. Effective management is essential for improving patient outcomes.
Addressing pruritus involves pharmacological treatments and lifestyle changes, tailored to individual patient needs, to alleviate symptoms and enhance well-being.
Long-term management of PBC requires a comprehensive approach, integrating symptom control with disease-modifying therapies to prevent complications and improve overall patient care.

The panel of experts discuss the role of effectively treating pruritus, a common and debilitating symptom in over 80% of patients with cholestatic liver diseases like primary biliary cholangitis (PBC), and its importance in the long-term management of the disease.

EP: 1.Pathophysiology of PBC

EP: 2.Presentation and Diagnosis of PBC

EP: 3.Differential Diagnosis of PBC

EP: 4.Disease Progression and Extrahepatic Manifestations of PBC

EP: 5.Second-Line Treatments and Management of Symptoms in PBC

EP: 6.Treatment Goals and First-Line Therapy in PBC

EP: 7.Seladelpar for Treatment of PBC

EP: 8.PPAR Agonists for Treatment of PBC

EP: 9.Elafibranor and Choosing Amongst PPAR Agonists in PBC

Now Viewing

EP: 10.Pruritus Control With PPAR Agonists in PBC

EP: 11.Integration of PPAR Agonists in Treatment Landscape of PBC

EP: 12.Treatment Response to PPAR Agonists and Other Therapies in PBC

EP: 13.Thoughts on the Current State of PBC Management

EP: 14.Outcomes and Adoption of PPAR Agonists in PBC

Video content above is prompted by the following:

Pruritus is a debilitating symptom experienced by over 80% of patients with cholestatic liver diseases, such as PBC. What is the role of effectively treating pruritus in the long-term management of PBC?